Although the use of biosimilars in rheumatoid diseases, inflammatory bowel diseases, and oncology has the potential to reduce treatment costs, a variety of factors may influence the adoption of biosimilar treatments. Capitalizing on our unique expertise in patient chart-based research, we have designed, with input from our clients, a new syndicated offering based on real world data to monitor the impact of biosimilar treatments on inflammatory conditions and cancer patient management.
Fill in the form below to access an overview of our Biosimilar syndicated studies including:
- Types of data collected
- Dates of research waves